✦ LIBER ✦

8051 Final results of a phase I study of pegylated liposomal doxorubicin + gemcitabine in prolonged infusion in patients with recurrent ovarian cancer less than one year

✍ Scribed by Lacave, A.J.; Crespo, G.; Fonseca, P.J.; Villanueva, N.; Berros, J.P.; Vieitez, J.M.; Esteban, E.; Losa, R.; Sierra, M.

Book ID: 122679892
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 49 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(09)71573-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Addition of vandetanib to pegylated lipo

Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)

✍ Harter, Philipp; Sehouli, Jalid; Kimmig, Rainer; Rau, JÃ¶rn; Hilpert, Felix; Kur 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 162 KB

Patient-reported outcomes in relapsed ov

Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone

✍ Carolyn N. Krasner; Andres Poveda; Thomas J. Herzog; Jan B. Vermorken; Stanley B 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 553 KB

179 A phase II second line study of lipo

179 A phase II second line study of liposomal doxorubicin and carboplatin in patients with recurrent ovarian cancer with a disease free interval equal or greater than 6 months

✍ D.A. Vorobiof; B.L. Rapoport; R. Mahomed; A. Uys; C. Slabber; R. Eek; G. Cohen; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 172 KB

Phase 3 randomised study of canfosfamide

Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer

✍ I. Vergote; N. Finkler; J. del Campo; A. Lohr; J. Hunter; D. Matei; J. Kavanagh; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 317 KB

Phase II, Open-Label, Randomized, Multic

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

✍ Kaye, S. B.; Lubinski, J.; Matulonis, U.; Ang, J. E.; Gourley, C.; Karlan, B. Y. 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 165 KB

8029 POSTER Health-Related Quality of Li

8029 POSTER Health-Related Quality of Life (HRQoL)/Patient Reported Outcomes (PRO) of Patients (pts) With Partially Platinum Sensitive (PPS) Recurrent Ovarian Cancer (ROC) Treated in a Randomized Phase III Trial of Trabectedin and Pegylated Liposomal Doxorubicin (PLD) Vs PLD Alone (OVA-301) – an Exploratory Analysis

✍ Verqote, I.; Bidzinski, M.; Kelley, J.; Vasanthan, S.; Runnebaum, I.; Vermorken, 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 45 KB